Feature | March 26, 2015

TAVR to Drive Rapid Market Growth for Prosthetic Valves

Market value projected to eclipse $3 billion by 2020

TAVR, transcatheter heart valves, GlobalData, TMVR

March 26, 2015 — Research and consulting firm GlobalData reported that the global market value for transcatheter heart valves will expand at a Compound Annual Growth Rate (CAGR) of 19.7 percent through 2020, reaching an approximate value of $3.02 billion.

The company’s report states that this is almost three times the projected value of the tissue heart valves market, which will increase at a much slower CAGR of 3.2 percent to just under $1.08 billion over the same period.

GlobalData’s forecast only considers aortic valve replacement, as there are not yet any approved transcatheter mitral valve replacement (TMVR) devices. The approval of TMVR devices will have a significant impact on this forecast, but early adoption rates are expected to be slow due to initial cost.

While surgical valves will hold a steady presence in the overall prosthetic valve market, transcatheter aortic valve replacement (TAVR) is expected to cannibalize a large portion of this market in the coming decade. As increasing competition drives down device costs, patients will subsequently have better access to minimally invasive treatment.

Premdharan Meyyan, GlobalData’s analyst covering medical devices, said that while first-generation devices have shown promising clinical outcomes to date, physicians have noted issues such as paravalvular regurgitation and a lack of repositionability.

Meyyan explained: “Transcatheter valves that are fully repositionable and retrievable address some of the main issues inherent in earlier products. Notable devices include Boston Scientific’s Lotus Valve System, Edwards Lifesciences’ Sapien 3, and Medtronic’s CoreValve Evolut R, the latter of which recently displayed a 6.5 percent improvement in all-cause mortality rate compared to open-heart surgery at the two-year mark.

“The adoption of these next-generation valves is expected to drive significant market growth, provided that clinical data continues to show positive mortality and morbidity outcomes for patients.”

The analyst added that as only high-risk or inoperable aortic valve disease patients are currently eligible for TAVR, more robust, long-term clinical data must be established before the treatment is offered to lower-risk patients.

“Until then, physicians will likely opt for the surgical option, as there is a multitude of clinical data proving efficacy. However, GlobalData believes it is likely that the indications for TAVR will expand and the technology will begin to dominate the surgical market over the forecast period,” Meyyan concluded.

For more information: www.globaldata.com

Related Content

Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
Feature | Heart Valve Technology | December 12, 2018
A jury in the U.S. District Court for the District of Delaware determined Dec. 11 that the Boston Scientific U.S....
First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
MitraClip Reduces Mortality for Heart Failure Patients With Secondary Mitral Regurgitation
News | Heart Valve Technology | September 26, 2018
Patients with heart failure and secondary mitral regurgitation (MR) who remained symptomatic despite maximally...
Ancora Heart Announces Positive Interim Analysis of AccuCinch Ventricular Repair System for Heart Failure
News | Heart Valve Technology | September 24, 2018
Ancora Heart Inc. announced positive clinical data from the company’s recently expanded U.S. early feasibility study...
Medtronic Announces TAVR Study of Aortic Stenosis Patients With Bicuspid Valves
News | Heart Valve Technology | September 19, 2018
The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a new...
4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018
News | Heart Valve Technology | September 17, 2018
September 17, 2018 — 4C Medical Technologies Inc.
Overlay Init